• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

蛋白酶体抑制剂PS-341通过JNK/c-Jun/AP-1信号通路诱导非小细胞肺癌细胞生长停滞和凋亡。

Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling.

作者信息

Yang Yang, Ikezoe Takeyuki, Saito Tsuyako, Kobayashi Makoto, Koeffler H Phillip, Taguchi Hirokuni

机构信息

Department of Internal Medicine, Kochi Medical School, Kochi 783-8505, Japan.

出版信息

Cancer Sci. 2004 Feb;95(2):176-80. doi: 10.1111/j.1349-7006.2004.tb03200.x.

DOI:10.1111/j.1349-7006.2004.tb03200.x
PMID:14965369
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11160053/
Abstract

Proteasome inhibitor PS-341 induces growth arrest and apoptosis of multiple myeloma (MM) cells via inactivation of NF-kappaB in vitro and has afforded some objective responses in individuals with relapsed, refractory MM. However, the activity of PS-341 against non-hematological malignancies remains to be fully elucidated. In this study, we found that PS-341 induced growth arrest and apoptosis of NCI-H520 and -H460 non-small cell lung cancer (NSCLC) cells in conjunction with markedly up-regulated levels of p21(waf1) and p53, and down-regulation of bcl-2 protein in these cells. Also, PS-341 caused phosphorylation of c-Jun NH(2)-terminal kinase (JNK) and c-Jun, and enhanced AP-1/DNA binding activities in these cells as measured by western blotting and enzyme-linked immunosorbent assay (ELISA), respectively. Interestingly, when the JNK/c-Jun/AP-1 signal pathway was disrupted by the JNK inhibitor SP600125, the ability of PS-341 to inhibit the growth of NSCLC cells and to up-regulate the levels of p21(waf1) in these cells was blunted, but the expression of p53 was sustained at a high level, suggesting that the JNK/c-Jun/AP-1 signal pathway might mediate the anti-lung cancer effects of PS-341, with p21(waf1) playing the central role. Thus, PS-341 might be useful for the treatment of individuals with NSCLC.

摘要

蛋白酶体抑制剂PS - 341在体外通过使核因子-κB失活诱导多发性骨髓瘤(MM)细胞生长停滞和凋亡,并且已使一些复发、难治性MM患者出现了客观反应。然而,PS - 341对非血液系统恶性肿瘤的活性仍有待充分阐明。在本研究中,我们发现PS - 341诱导NCI - H520和 - H460非小细胞肺癌(NSCLC)细胞生长停滞和凋亡,同时这些细胞中p21(waf1)和p53水平显著上调,bcl - 2蛋白下调。此外,PS - 341导致c - Jun氨基末端激酶(JNK)和c - Jun磷酸化,并且分别通过蛋白质印迹法和酶联免疫吸附测定(ELISA)检测发现这些细胞中AP - 1/DNA结合活性增强。有趣的是,当JNK抑制剂SP600125阻断JNK/c - Jun/AP - 1信号通路时,PS - 341抑制NSCLC细胞生长以及上调这些细胞中p21(waf1)水平的能力减弱,但p53的表达维持在高水平,这表明JNK/c - Jun/AP - 1信号通路可能介导PS - 341的抗肺癌作用,其中p21(waf1)起核心作用。因此,PS - 341可能对NSCLC患者的治疗有用。

相似文献

1
Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling.蛋白酶体抑制剂PS-341通过JNK/c-Jun/AP-1信号通路诱导非小细胞肺癌细胞生长停滞和凋亡。
Cancer Sci. 2004 Feb;95(2):176-80. doi: 10.1111/j.1349-7006.2004.tb03200.x.
2
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.蛋白酶体抑制剂PS-341诱导人非小细胞肺癌细胞系G(2)-M期阻滞和凋亡的机制
Clin Cancer Res. 2003 Mar;9(3):1145-54.
3
JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.JNK和AP-1通过FasL/半胱天冬酶-8和线粒体依赖性途径介导硼替佐米诱导的HepG2细胞凋亡。
Apoptosis. 2006 Apr;11(4):607-25. doi: 10.1007/s10495-006-4689-y.
4
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.介导蛋白酶体抑制剂PS-341抗骨髓瘤活性的分子机制。
Blood. 2003 Feb 15;101(4):1530-4. doi: 10.1182/blood-2002-08-2543. Epub 2002 Sep 26.
5
Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells.蛋白酶体抑制剂PS-341可下调前列腺特异性抗原(PSA),并诱导雄激素依赖性人前列腺癌LNCaP细胞生长停滞和凋亡。
Cancer Sci. 2004 Mar;95(3):271-5. doi: 10.1111/j.1349-7006.2004.tb02215.x.
6
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.蛋白酶体抑制剂硼替佐米与组蛋白去乙酰化酶抑制剂协同诱导人多发性骨髓瘤细胞氧化损伤和凋亡
Clin Cancer Res. 2004 Jun 1;10(11):3839-52. doi: 10.1158/1078-0432.CCR-03-0561.
7
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.蛋白酶体抑制剂硼替佐米对髓样和间变性甲状腺癌细胞的体外抗肿瘤作用
J Clin Endocrinol Metab. 2006 Oct;91(10):4013-21. doi: 10.1210/jc.2005-2472. Epub 2006 Jul 18.
8
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).蛋白酶体抑制剂PS-341可导致多形性胶质母细胞瘤(GBM)细胞生长停滞和凋亡。
Oncogene. 2005 Jan 13;24(3):344-54. doi: 10.1038/sj.onc.1208225.
9
MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.MKP1 抑制是 NF-κB 和 PI3K 抑制剂增强非小细胞肺癌对顺铂化疗敏感性所必需的。
Cancer Lett. 2009 Dec 28;286(2):206-16. doi: 10.1016/j.canlet.2009.05.029. Epub 2009 Jun 23.
10
[The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment].[雷洛昔芬对人前列腺癌细胞增殖抑制作用中丝裂原活化蛋白激酶级联反应的作用:一项体外实验]
Zhonghua Yi Xue Za Zhi. 2008 Jan 22;88(4):271-5.

引用本文的文献

1
[Research and Therapeutic Advances of 26S Proteasome Subunit 
in Non-small Cell Lung Cancer].[26S蛋白酶体亚基在非小细胞肺癌中的研究与治疗进展]
Zhongguo Fei Ai Za Zhi. 2025 May 20;28(5):363-370. doi: 10.3779/j.issn.1009-3419.2025.106.13.
2
Bortezomib exerts its anti-cancer activity through the regulation of Skp2/p53 axis in non-melanoma skin cancer cells and C. elegans.硼替佐米通过调控非黑色素瘤皮肤癌细胞和秀丽隐杆线虫中的Skp2/p53轴发挥其抗癌活性。
Cell Death Discov. 2024 May 9;10(1):225. doi: 10.1038/s41420-024-01992-7.
3
The role of proteasomes in tumorigenesis.蛋白酶体在肿瘤发生中的作用。
Genes Dis. 2023 Aug 6;11(4):101070. doi: 10.1016/j.gendis.2023.06.037. eCollection 2024 Jul.
4
Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies.硼替佐米治疗多发性骨髓瘤的耐药性及新兴技术的潜在作用综述
Pharmaceuticals (Basel). 2023 Jan 12;16(1):111. doi: 10.3390/ph16010111.
5
Advances in Proteasome Enhancement by Small Molecules.小分子增强蛋白酶体的研究进展。
Biomolecules. 2021 Nov 30;11(12):1789. doi: 10.3390/biom11121789.
6
Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells.硼替佐米对蛋白酶体的抑制作用类似于减少头颈部癌细胞的生长,并增加肿瘤浸润免疫细胞。
Sci Rep. 2021 Sep 24;11(1):19051. doi: 10.1038/s41598-021-98450-6.
7
Uncovering the Anti-Lung-Cancer Mechanisms of the Herbal Drug FDY2004 by Network Pharmacology.基于网络药理学揭示中药FDY2004的抗肺癌机制
Evid Based Complement Alternat Med. 2021 Feb 4;2021:6644018. doi: 10.1155/2021/6644018. eCollection 2021.
8
Establishment of the prognostic index of lung squamous cell carcinoma based on immunogenomic landscape analysis.基于免疫基因组图谱分析建立肺鳞状细胞癌的预后指数
Cancer Cell Int. 2020 Jul 20;20:330. doi: 10.1186/s12935-020-01429-y. eCollection 2020.
9
Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?利用肺癌中 p53 突变体的弱点 - 聚焦蛋白酶体:以旧敌为新招?
Cancer Biol Ther. 2020 Apr 2;21(4):293-302. doi: 10.1080/15384047.2019.1702403. Epub 2020 Feb 10.
10
Identification of key candidate tumor biomarkers in non-small-cell lung cancer by analysis.通过分析鉴定非小细胞肺癌中的关键候选肿瘤生物标志物。
Oncol Lett. 2020 Jan;19(1):1008-1016. doi: 10.3892/ol.2019.11169. Epub 2019 Dec 2.

本文引用的文献

1
Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells.冬凌草甲素可诱导多种人类癌细胞的生长抑制和凋亡。
Int J Oncol. 2003 Oct;23(4):1187-93.
2
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.蛋白酶体抑制剂PS-341诱导人非小细胞肺癌细胞系G(2)-M期阻滞和凋亡的机制
Clin Cancer Res. 2003 Mar;9(3):1145-54.
3
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.蛋白酶体抑制剂PS-341显著增强多发性骨髓瘤肿瘤细胞对化疗药物的敏感性。
Clin Cancer Res. 2003 Mar;9(3):1136-44.
4
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.蛋白酶体抑制剂PS - 341用于难治性血液系统恶性肿瘤患者的I期试验。
J Clin Oncol. 2002 Nov 15;20(22):4420-7. doi: 10.1200/JCO.2002.01.133.
5
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.蛋白酶体抑制剂PS-341增强多发性骨髓瘤细胞对传统化疗药物的敏感性:治疗应用。
Blood. 2003 Mar 15;101(6):2377-80. doi: 10.1182/blood-2002-06-1768. Epub 2002 Nov 7.
6
Proteasome inhibitors as new anticancer drugs.蛋白酶体抑制剂作为新型抗癌药物。
Curr Opin Oncol. 2002 Nov;14(6):628-34. doi: 10.1097/00001622-200211000-00007.
7
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.介导蛋白酶体抑制剂PS-341抗骨髓瘤活性的分子机制。
Blood. 2003 Feb 15;101(4):1530-4. doi: 10.1182/blood-2002-08-2543. Epub 2002 Sep 26.
8
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.蛋白酶体抑制对人多发性骨髓瘤细胞的分子后遗症
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9. doi: 10.1073/pnas.202445099. Epub 2002 Oct 21.
9
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.蛋白酶体抑制剂PS-341在体内可抑制人骨髓瘤细胞生长,并延长小鼠模型的生存期。
Cancer Res. 2002 Sep 1;62(17):4996-5000.
10
Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer.蛋白酶体抑制剂PS-341用于癌症治疗的临床前和临床评估。
Curr Opin Chem Biol. 2002 Aug;6(4):493-500. doi: 10.1016/s1367-5931(02)00343-5.